BR9907855A - Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal - Google Patents
Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animalInfo
- Publication number
- BR9907855A BR9907855A BR9907855-4A BR9907855A BR9907855A BR 9907855 A BR9907855 A BR 9907855A BR 9907855 A BR9907855 A BR 9907855A BR 9907855 A BR9907855 A BR 9907855A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- conjugate
- particle
- modified hepatitis
- core
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 101710132601 Capsid protein Proteins 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title abstract 2
- 231100000283 hepatitis Toxicity 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000002054 inoculum Substances 0.000 title 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract 3
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000011081 inoculation Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/894—Manufacture, treatment, or detection of nanostructure having step or means utilizing biological growth
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7453798P | 1998-02-12 | 1998-02-12 | |
PCT/US1999/003055 WO1999040934A1 (en) | 1998-02-12 | 1999-02-11 | Strategically modified hepatitis b core proteins and their derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9907855A true BR9907855A (pt) | 2001-04-24 |
Family
ID=22120092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9907855-4A BR9907855A (pt) | 1998-02-12 | 1999-02-11 | Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal |
Country Status (20)
Country | Link |
---|---|
US (1) | US6231864B1 (pt) |
EP (1) | EP1054689B1 (pt) |
JP (1) | JP4480268B2 (pt) |
KR (1) | KR100581991B1 (pt) |
CN (1) | CN100387622C (pt) |
AT (1) | ATE249240T1 (pt) |
AU (1) | AU767144B2 (pt) |
BR (1) | BR9907855A (pt) |
CA (1) | CA2320488C (pt) |
CZ (1) | CZ302092B6 (pt) |
DE (1) | DE69911175T2 (pt) |
DK (1) | DK1054689T3 (pt) |
ES (1) | ES2207177T3 (pt) |
HK (1) | HK1038306A1 (pt) |
ID (1) | ID26669A (pt) |
IL (2) | IL137766A0 (pt) |
NZ (1) | NZ506245A (pt) |
PT (1) | PT1054689E (pt) |
TR (1) | TR200002338T2 (pt) |
WO (1) | WO1999040934A1 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
CN1193791C (zh) | 1998-11-30 | 2005-03-23 | 希托斯生物技术股份公司 | 抗原的有序分子呈递,制备及使用的方法 |
JP2003520568A (ja) * | 1999-02-02 | 2003-07-08 | バイオカシェ ファーマシューティカルズ, インコーポレイテッド | 高度な抗原提示プラットフォーム |
US6887464B1 (en) * | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
WO2001016174A2 (en) * | 1999-08-30 | 2001-03-08 | Rolf Kiessling | Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65 |
CN1254541C (zh) | 2000-02-23 | 2006-05-03 | 史密丝克莱恩比彻姆生物有限公司 | 新化合物 |
AU2001252458A1 (en) * | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
ATE396265T1 (de) | 2000-06-28 | 2008-06-15 | Corixa Corp | Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs |
US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
NZ527664A (en) * | 2001-02-05 | 2006-12-22 | Stressgen Biotechnologies Corp | Hepatitis B virus vaccine comprising a stress protein and an HBV antigen |
EP1988097A1 (en) | 2001-05-09 | 2008-11-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20030175863A1 (en) * | 2001-08-15 | 2003-09-18 | Birkett Ashley J. | Influenza immunogen and vaccine |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
US20030037327A1 (en) * | 2001-08-15 | 2003-02-20 | International Business Machines Corporation | Run-time rule-based topological installation suite |
US20040146524A1 (en) * | 2002-02-21 | 2004-07-29 | Katelynne Lyons | Stabilized immunogenic HBc chimer particles |
EP2196217A1 (en) | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
JP4360906B2 (ja) * | 2001-09-14 | 2009-11-11 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化 |
US7115266B2 (en) * | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
BR0213117A (pt) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Conjugados peptìdeo angiotensina-veìculo e seus usos |
AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
AU2003212985A1 (en) * | 2002-02-08 | 2003-09-02 | New York University | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies |
EP1517702A4 (en) * | 2002-02-21 | 2006-05-03 | Apovia Inc | IMMUNOGENIC HBC CHIMERIC PARTICLES STABILIZED WITH AN N-TERMINAL END CYSTEINE |
WO2003072731A2 (en) * | 2002-02-21 | 2003-09-04 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
WO2003072722A2 (en) * | 2002-02-21 | 2003-09-04 | Apovia, Inc. | IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY |
CA2488856A1 (en) * | 2002-06-20 | 2003-12-31 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
JP4726483B2 (ja) | 2002-07-17 | 2011-07-20 | サイトス バイオテクノロジー アーゲー | 分子抗原アレイ |
AU2003250106B2 (en) * | 2002-07-18 | 2009-11-26 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
EP2338510A1 (en) * | 2002-07-19 | 2011-06-29 | Novartis Pharma AG | Vaccine compositions containing amyloid beta1-6 antigen arrays |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
BRPI0408623A (pt) * | 2003-03-26 | 2006-03-07 | Cytos Biotechnology Ag | conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a |
US20070087331A1 (en) * | 2003-05-15 | 2007-04-19 | Cytos Biotechnology Ag | Selection of b cells with specificity if interest: method of preparation and use |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US7883843B2 (en) | 2003-07-30 | 2011-02-08 | Vaccine Research Institute Of San Diego | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
US7320795B2 (en) | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
CN1305527C (zh) * | 2003-11-21 | 2007-03-21 | 薛平 | 乙型肝炎治疗疫苗及其制备方法 |
ZA200604663B (en) * | 2004-01-20 | 2008-02-27 | Cytos Biotechnology Ag | Particle-induced ghrelin immune response |
US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
AU2005287383B2 (en) * | 2004-05-25 | 2011-09-22 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
CA2837748C (en) | 2004-05-25 | 2016-03-08 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
JP5524610B2 (ja) | 2006-04-07 | 2014-06-18 | ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク | トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法 |
US8067011B2 (en) * | 2006-04-07 | 2011-11-29 | Chimeros, Inc. | Compositions and methods for treating B-cell malignancies |
WO2008124165A2 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
EA026787B1 (ru) * | 2007-08-27 | 2017-05-31 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Конструкция нуклеиновой кислоты и ее применение для лечения, предотвращения и сдерживания болезни альцгеймера |
EP2240199A4 (en) * | 2008-02-09 | 2012-10-03 | Sanofi Pasteur Biologics Llc | INFLUENZA VACCINES |
CN101423555B (zh) * | 2008-11-14 | 2011-04-20 | 四川大学华西医院 | 特异性阻断乙肝病毒组装和复制的膜穿透性多肽 |
NZ592977A (en) | 2008-12-09 | 2013-01-25 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
WO2010086743A2 (en) | 2009-02-02 | 2010-08-05 | Chrontech Pharma Ab | Compositions and methods that enhance an immune response |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
EP2459214A1 (en) * | 2009-07-30 | 2012-06-06 | Pfizer Vaccines LLC | Antigenic tau peptides and uses thereof |
RU2538162C2 (ru) | 2009-09-03 | 2015-01-10 | Пфайзер Вэксинс ЭлЭлСи | Вакцина против pcsk9 |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
CN103608030A (zh) | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | 用于治疗和诊断癌症的组合物和方法 |
WO2013036973A2 (en) | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
JP6374387B2 (ja) * | 2012-08-21 | 2018-08-15 | ヤンセン ファーマシューティカ エヌ.ベー. | リスペリドンハプテンへの抗体及びその使用 |
CA2936092A1 (en) * | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
CA2906778A1 (en) | 2013-03-15 | 2014-09-18 | Vlp Biotech, Inc. | Rodent hepadnavirus cores with reduced carrier-specific antigenicity |
US20160039883A1 (en) * | 2013-03-15 | 2016-02-11 | Medimmune, Llc | Palivizumab epitope-based virus-like particles |
GB201402890D0 (en) | 2014-02-18 | 2014-04-02 | Iqur Ltd | Vaccines based on hepatitis B Core antigens |
CN104208670B (zh) * | 2014-09-09 | 2017-07-28 | 韩自勤 | 一种治疗乙肝的药物组合物 |
GB201505041D0 (en) * | 2015-03-25 | 2015-05-06 | Iqur Ltd | Vaccines based on hepatitis B core antigens |
CN107383176A (zh) * | 2017-05-10 | 2017-11-24 | 于学杰 | 用于对汉滩病毒和汉城病毒引起的肾综合征出血热分型的多肽 |
BR112019027737A2 (pt) * | 2017-06-23 | 2020-09-15 | American Type Culture Collection (Atcc) | partículas semelhantes a vírus compreendendo antígenos de zika |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
EP3851120A4 (en) | 2018-09-11 | 2022-04-27 | Shanghai Public Health Clinical Center | IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF |
CN114127121A (zh) | 2019-08-12 | 2022-03-01 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
CN110804097B (zh) * | 2019-10-30 | 2021-02-26 | 云南沃森生物技术股份有限公司 | 一种同时制备两种单克隆抗体的方法 |
US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR73675B (pt) | 1978-12-22 | 1984-03-29 | Biogen Inc | |
US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
GB8903313D0 (en) * | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
US5840303A (en) * | 1991-08-26 | 1998-11-24 | The Scripps Research Foundation | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
WO1998009649A1 (en) * | 1996-09-03 | 1998-03-12 | The General Hospital Corporation | Inhibition of viral replication |
-
1999
- 1999-02-11 BR BR9907855-4A patent/BR9907855A/pt not_active IP Right Cessation
- 1999-02-11 ES ES99906969T patent/ES2207177T3/es not_active Expired - Lifetime
- 1999-02-11 DK DK99906969T patent/DK1054689T3/da active
- 1999-02-11 NZ NZ506245A patent/NZ506245A/en unknown
- 1999-02-11 PT PT99906969T patent/PT1054689E/pt unknown
- 1999-02-11 AU AU26753/99A patent/AU767144B2/en not_active Ceased
- 1999-02-11 AT AT99906969T patent/ATE249240T1/de active
- 1999-02-11 KR KR1020007008848A patent/KR100581991B1/ko not_active IP Right Cessation
- 1999-02-11 IL IL13776699A patent/IL137766A0/xx active IP Right Grant
- 1999-02-11 DE DE69911175T patent/DE69911175T2/de not_active Expired - Lifetime
- 1999-02-11 CN CNB998049727A patent/CN100387622C/zh not_active Expired - Fee Related
- 1999-02-11 CZ CZ20002819A patent/CZ302092B6/cs not_active IP Right Cessation
- 1999-02-11 TR TR2000/02338T patent/TR200002338T2/xx unknown
- 1999-02-11 JP JP2000531185A patent/JP4480268B2/ja not_active Expired - Lifetime
- 1999-02-11 US US09/248,588 patent/US6231864B1/en not_active Expired - Lifetime
- 1999-02-11 EP EP99906969A patent/EP1054689B1/en not_active Expired - Lifetime
- 1999-02-11 WO PCT/US1999/003055 patent/WO1999040934A1/en not_active Application Discontinuation
- 1999-02-11 ID IDW20001759A patent/ID26669A/id unknown
- 1999-02-11 CA CA002320488A patent/CA2320488C/en not_active Expired - Fee Related
-
2000
- 2000-08-08 IL IL137766A patent/IL137766A/en unknown
-
2002
- 2002-01-08 HK HK01107006.6A patent/HK1038306A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010052165A (ko) | 2001-06-25 |
EP1054689A4 (en) | 2002-02-13 |
EP1054689A1 (en) | 2000-11-29 |
DE69911175T2 (de) | 2004-07-29 |
TR200002338T2 (tr) | 2002-06-21 |
DK1054689T3 (da) | 2004-01-26 |
ATE249240T1 (de) | 2003-09-15 |
DE69911175D1 (de) | 2003-10-16 |
JP2002509700A (ja) | 2002-04-02 |
CA2320488A1 (en) | 1999-08-19 |
WO1999040934A1 (en) | 1999-08-19 |
CN1300222A (zh) | 2001-06-20 |
NZ506245A (en) | 2003-08-29 |
US6231864B1 (en) | 2001-05-15 |
IL137766A (en) | 2007-12-03 |
IL137766A0 (en) | 2001-10-31 |
KR100581991B1 (ko) | 2006-05-23 |
ES2207177T3 (es) | 2004-05-16 |
JP4480268B2 (ja) | 2010-06-16 |
HK1038306A1 (en) | 2002-03-15 |
ID26669A (id) | 2001-01-25 |
AU767144B2 (en) | 2003-10-30 |
CA2320488C (en) | 2007-03-06 |
AU2675399A (en) | 1999-08-30 |
CZ20002819A3 (en) | 2001-06-13 |
PT1054689E (pt) | 2003-11-28 |
CN100387622C (zh) | 2008-05-14 |
EP1054689B1 (en) | 2003-09-10 |
CZ302092B6 (cs) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9907855A (pt) | Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal | |
HUP0004327A1 (en) | Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions | |
NO932644L (no) | Antigen-presenterende kapsid med fusert ms2-kappeprotein | |
ATE162402T1 (de) | Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff | |
BR9911397A (pt) | Utilização de partìculas de proteìnas invólucro de hcv para vacinação | |
DE69731386D1 (de) | Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin | |
GR3030568T3 (en) | Inducing cytotoxic t lymphocyte responses. | |
Keljo et al. | Characterization of Binding of Simian Rotavirus SA‐11 to Cultured Epithelial Cells | |
BRPI0407636A (pt) | meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus | |
PT96097A (pt) | Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados | |
FI884889A0 (fi) | Foerfarande foer framstaellning av en sammansaettning av amfotericin b och kolesterolsulfat. | |
CN109182262A (zh) | 一种间充质干细胞无血清培养基 | |
GB2108527A (en) | Non-a non-b hepatitis virus | |
Hirschman | Integrator enzyme hypothesis for replication of hepatitis-B virus | |
Kumon | Morphologically recognizable markers for scanning immunoelectron microscopy: II. An indirect method using T4 and TMV | |
ES2063200T3 (es) | Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo. | |
PE78799A1 (es) | Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol | |
ATE68601T1 (de) | Reagenz zur bestimmung durch haemagglutination von antikoerpern gegen bakterien-toxine, verfahren zu ihrer herstellung und verwendung. | |
FI923020A (fi) | Inte a inte b-sekvenser. | |
DE3888887D1 (de) | Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung. | |
Lewis et al. | Microcultures of Sarotherodon mossambicus (Peters) cells: their use in detecting fish viruses. | |
DE59610968D1 (de) | Zellinie und verfahren zur vermehrung von tollwutviren und deren quantitativen nachweis | |
DE69121933D1 (de) | Nukleinsäuren, Antigene und Antikörper betreffend Non-A, Non-B Hepatitis und deren Nachweisreagenzien | |
Sun et al. | Research on the flow around the bluff bodies and flow induced vibrations | |
BR0215013A (pt) | Biomassa particulada de embrião aviário para a produção de antìgenos de vìrus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO COM BASE NO ARTIGO 22 DA LPI VIGENTE. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 14A E 15A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ATE A 21A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |